talimogene laherparepvec

AXP000001.2 · Oncolytic virus

Platform
HSV-1 (JS1 strain, ICP34.5- ICP47-)
Originator
BioVex
Sponsor
Amgen

Names

NameTypeSource
talimogene laherparepvecpreferred name, INNcurator, ncit
Imlygicbrandncit
JS1 34.5-hGMCSF 47- pA-codencit
T-VECsynonymncit
OncoVEX GM-CSFformer codencit

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Strain
JS1
Replication
conditionally replicating
Modifications
RL1 (ICP34.5) deleted in both copies; US12 (ICP47) deleted, placing US11 under the ICP47 promoter
Transgenes
CSF2
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C61314
Wikidata
Q7679524
FDA UNII
07730V90L6

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2015-10-27approvedImlygicLocal treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgerysource
EMAEU2015-12approvedImlygicUnresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral diseasesource

Clinical trials (55)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07102394Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1RecruitingPhase 12026-02-012026-1210Cutaneous Neurofibroma; NF1; Neurofibroma; Neurofibromas; Neurofibromatosis; Von Recklinghausen Disease
NCT06660810Neoadjuvant Intralesional Injection of Talimogene LaherparepvecActive not recruitingPhase 22025-03-032026-05-262Sarcoma,Soft Tissue; Soft Tissue Sarcoma
NCT04065152Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi SarcomaUnknownPhase 22021-01-012023-02-0120Kaposi Sarcoma
NCT04599062TVEC and Preop Radiation for Sarcoma (8 ml Dose)Active not recruitingPhase 1/22020-09-102023-02-078Soft Tissue Sarcoma
NCT04330430Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable DiseaseCompletedPhase 22020-09-082023-04-0924Melanoma Stage III; Melanoma Stage IV
NCT04427306Neoadjuvant T-VEC in High Risk Early MelanomaSuspendedPhase 22020-05-212022-06-276Melanoma
NCT03554044T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerCompletedPhase 12020-02-052023-12-3120Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma
NCT04163952Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the SkinTerminatedPhase 12020-01-312025-03-285Locally Advanced Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Recurrent Skin Squamous Cell Carcinoma
NCT04068181Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).CompletedPhase 22020-01-222021-08-1972Melanoma
NCT02923778Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by SurgeryActive not recruitingPhase 22019-12-312026-12-2940Leiomyosarcoma; Liposarcoma; Sarcoma G2; Sarcoma G3; Soft Tissue Sarcoma; Soft Tissue Sarcoma of the Trunk and Extremities; Stage I Soft Tissue Sarcoma AJCC v7; Stage II Soft Tissue Sarcoma AJCC v7; Undifferentiated Pleomorphic Sarcoma
NCT03921073Study of T-VEC in Locally Advanced Cutaneous AngiosarcomaTerminatedPhase 22019-08-202021-09-285Angiosarcoma of Skin
NCT04185311Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedTerminatedPhase 12019-07-102023-05-176Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; HER2/Neu Negative; Invasive Ductal Carcinoma, Not Otherwise Specified; Progesterone Receptor Negative; Prognostic Stage 0 Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma
NCT03842943Neoadjuvant Combination Immunotherapy for Stage III MelanomaRecruitingPhase 22019-07-032026-06-0128Cutaneous Melanoma
NCT03972046Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant MelanomaWithdrawnPhase 22019-06-242020-02-030BRAF Gene Mutation; Melanoma (Skin); Melanoma Stage IIIb-IVM1a; Metastasis Skin; Tumor Skin
NCT03663712Talimogene Laherparepvec for the Treatment of Peritoneal Surface MalignanciesCompletedPhase 12019-05-232022-10-1328Peritoneal Surface Malignancy
NCT03886311Talimogene Laherparepvec, Nivolumab and Trabectedin for SarcomaRecruitingPhase 22019-05-152030-12-31200Sarcoma
NCT03300544Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal CancerTerminatedPhase 12019-05-142022-03-223Locally Advanced Rectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Rectal Adenocarcinoma; Stage III Rectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7
NCT03597009A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural EffusionTerminatedPhase 1/22019-03-062020-02-071Lung Cancer; Malignant Pleural Effusion; Stage IV Metastatic Cancer
NCT03714828Study of TVEC in Patients With Cutaneous Squamous Cell CancerCompletedPhase 22018-12-202023-07-1911Cutaneous Tumor; Keratoacanthoma; Lesion Skin; Skin Cancer; Skin Cancer, Squamous Cell; Squamous Cell Carcinoma
NCT03802604Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerCompletedEarly phase 12018-12-102022-04-2728Breast Cancer
NCT03747744Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)UnknownPhase 12018-09-282023-10-0118Melanoma
NCT03555032TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)CompletedPhase 1/22018-06-262021-08-0115Melanoma and Sarcoma
NCT02965716Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaActive not recruitingPhase 22018-06-052023-06-3043Advanced Melanoma; Recurrent Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
NCT03430687Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell CarcinomaWithdrawnPhase 12018-06-012019-12-310Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7; Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7; Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7; Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
NCT03458117T-VEC in Non-melanoma Skin CancerCompletedPhase 12018-04-192022-02-0426Basal Cell Carcinoma; Cutaneous Lymphoma; Merkel Cell Carcinoma; Non-melanoma Skin Cancer; Squamous Cell Carcinoma
NCT03256344Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesCompletedPhase 12018-03-192020-05-2636Metastatic Colorectal Cancer; Metastatic Triple Negative Breast Cancer
NCT03086642Study of Talimogene Laherparepvec (T-VEC) in Pancreatic CancerCompletedPhase 12017-11-162021-05-1310Pancreatic Cancer
NCT02978625Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive not recruitingPhase 22017-09-272027-09-0168Anaplastic Large Cell Lymphoma, ALK-Negative; Anaplastic Large Cell Lymphoma, ALK-Positive; Apocrine Carcinoma; Carcinoma Arising From Cylindroma; Carcinoma Arising From Spiradenoma; Digital Papillary Adenocarcinoma; Endocrine Mucin-Producing Sweat Gland Carcinoma; Extramammary Paget Disease; Extraocular Sebaceous Carcinoma; Hidradenocarcinoma; Malignant Sweat Gland Neoplasm; Merkel Cell Carcinoma; Microcystic Adnexal Carcinoma; NK-Cell Lymphoma, Unclassifiable; Papillary Adenocarcinoma; Porocarcinoma; Primary Cutaneous Mucinous Carcinoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Merkel Cell Carcinoma; Refractory Mycosis Fungoides; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Skin Squamous Cell Carcinoma; Refractory T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; Signet Ring Cell Adenocarcinoma; Skin Adenoid Cystic Carcinoma; Skin Adnexal Carcinoma; Skin Basal Cell Carcinoma; Skin Basosquamous Cell Carcinoma; Skin Keratoacanthoma; Skin Squamous Cell Carcinoma; Squamoid Eccrine Ductal Carcinoma; Squamous Cell Carcinoma of Unknown Primary; Sweat Gland Carcinoma; Trichilemmal Carcinoma; Vulvar Squamous Cell Carcinoma
NCT02756845Study of Talimogene Laherparepvec In Children With Advanced Non CNS TumorsCompletedPhase 12017-08-162022-01-1715Advanced Non CNS Tumors
NCT02910557Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic InfectionCompleted2017-08-102026-01-30187Herpetic Infection; Melanoma
NCT03088176Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced MelanomaUnknownPhase 12017-06-252020-11-304BRAF Gene Mutation; Melanoma
NCT02779855Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast CancerCompletedPhase 1/22017-05-022020-09-2050Breast Cancer; Ductal Carcinoma; Invasive Breast Carcinoma; Invasive Ductal Breast Carcinoma
NCT03064763Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant MelanomaCompletedPhase 12017-03-072020-08-0318Unresectable Stage IIIB-IV Malignant Melanoma
NCT03069378A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive not recruitingPhase 22017-03-032025-07-2241Cutaneous Angiosarcoma; Epithelioid Sarcoma; Sarcoma
NCT02890368Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesTerminatedPhase 12016-092020-03-3156Breast Carcinoma; Human Papillomavirus-Related Malignant Neoplasm; Melanoma; Merkel-cell Carcinoma; Mycosis Fungoides; Soft Tissue Sarcoma; Solid Tumors; Squamous Cell Carcinoma
NCT02658812Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by SurgeryTerminatedPhase 22016-08-012021-12-0111Malignant Chest Wall Neoplasm; Recurrent Breast Carcinoma; Recurrent Inflammatory Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Inflammatory Breast Carcinoma
NCT02819843A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsCompletedPhase 22016-06-212024-02-2219Melanoma; Merkel Cell Carcinoma; Other Solid Tumors
NCT02626000Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)CompletedPhase 12016-04-062017-11-0236Carcinoma of the Head and Neck
NCT02509507Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611CompletedPhase 1/22016-02-052022-02-14127Cutaneous or Subcutaneous Lymph Node; Hepatocellular Carcinoma; Liver Metastases; Liver Tumors
NCT02453191TVEC and Preop Radiation for Sarcoma (4 ml Dose)CompletedPhase 1/22015-07-132019-01-2230Soft Tissue Sarcoma
NCT02366195Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected MelanomaCompletedPhase 22015-04-072017-06-26112Unresected Stage IIIb to IVM1c Melanoma
NCT02288897PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous MelanomaTerminatedPhase 32015-042019-0420Cutaneous Melanoma
NCT02211131Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for MelanomaCompletedPhase 22015-02-032019-04-30150Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
NCT02263508Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected MelanomaTerminatedPhase 32014-12-082021-03-11713Melanoma
NCT02014441Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene LaherparepvecCompletedPhase 22014-04-072016-01-2561Melanoma
NCT01740297Ipilimumab With or Without Talimogene Laherparepvec in Unresected MelanomaCompletedPhase 1/22013-02-072016-08-23217Melanoma
NCT01161498Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck CancerTerminatedPhase 32011-022011-105Head and Neck Cancer; Squamous Cell Carcinoma
NCT01368276An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in MelanomaCompletedPhase 32010-102014-0931Melanoma
NCT02173171Registry Study for Talimogene LaherparepvecCompleted2010-04-272021-09-23185Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
NCT00769704Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in MelanomaCompletedPhase 32009-042013-02437Melanoma
NCT02574260An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)CompletedPhase 22008-082010-013Melanoma
NCT00402025Talimogene Laherparepvec in Patients With Unresectable Pancreatic CancerCompletedPhase 12006-112008-0117Pancreatic Cancer
NCT00289016A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant MelanomaCompletedPhase 22005-122008-1250Melanoma
NCT02297529Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c MelanomaNo longer availableUnresected Stage IIIB to IVM1c Melanoma
NCT02147951Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c MelanomaNo longer availableUnresected Stage IIIb to IVM1c Melanoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40910408Clinical Pharmacology Characterization of the First-In-Class Oncolytic Viral Therapy T-VEC in Adults and Pediatric Subjects.Journal of clinical pharmacology2026name in title: T-VEC
PMID 41240988A single-arm phase 2 study of talimogene laherparepvec in patients with lower-risk invasive cutaneous squamous cell cancer.Journal of the American Academy of Dermatology2026name in title: talimogene laherparepvec
PMID 41698899Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).Nature communications2026cited by trial NCT03802604
PMID 42130226Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer.Journal of surgical oncology2026name in abstract: talimogene laherparepvec
PMID 42254311Acral lentiginous melanoma metastases to the vitreous masquerading as uveitis: A case report.American journal of ophthalmology case reports2026name in abstract: talimogene laherparepvec
PMID 42257503Talimogene Laherparepvec Response in Recurrent Melanoma During Corticosteroid Replacement for Immune Checkpoint Inhibitor-Induced Adrenal Insufficiency: A Case Report.Journal of immunotherapy (Hagerstown, Md. : 1997)2026name in title: talimogene laherparepvec
PMID 42437516Outcomes of Talimogene Laherparepvec in Soft Tissue Sarcoma.Journal of surgical oncology2026name in title: talimogene laherparepvec
PMID 42618312Complete tumour regression of in-transit melanoma following discontinuation of talimogene laherparepvec.BMJ case reports2026name in title: talimogene laherparepvec
PMID 39522025A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases.Cancer2025name in abstract: talimogene laherparepvec
PMID 39673447Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer.The oncologist2025cited by trial NCT03086642
PMID 39820126Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial).Nature cancer2025name in title: talimogene laherparepvec
PMID 40132906Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma.Journal for immunotherapy of cancer2025name in abstract: talimogene laherparepvec
PMID 40156118Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma.The oncologist2025cited by trial NCT02509507
PMID 40417130Talimogene laherparepvec induced bullous pemphigoid.JAAD case reports2025name in title: talimogene laherparepvec
PMID 40945432Quantitative habitat concentration analysis of triple negative breast cancer on MRI correlates with pathologic response to combination neoadjuvant immuno/chemotherapy.Clinical imaging2025name in abstract: talimogene laherparepvec
PMID 41005981Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.Journal for immunotherapy of cancer2025name in abstract: talimogene laherparepvec
PMID 41170453Talimogene Laherparepvec treatment for mucosal melanoma with metastatic lymph node metastasis: case report.Frontiers in oncology2025name in title: talimogene laherparepvec
PMID 41271741Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer.NPJ breast cancer2025cited by trial NCT03554044
PMID 41312331Recurrent melanoma presenting as a rash: a case report.Skin health and disease2025name in abstract: talimogene laherparepvec
PMID 38144943Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec.JAAD case reports2024name in title: talimogene laherparepvec
PMID 38577494Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec.JAAD case reports2024name in title: talimogene laherparepvec
PMID 38664936Successful Treatment of Metastatic Primary Cutaneous Adnexal Carcinoma With a PD-1 Inhibitor.Journal of immunotherapy (Hagerstown, Md. : 1997)2024cited by trial NCT02978625
PMID 38693123Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.Nature communications2024name in title: talimogene laherparepvec
PMID 38778387Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.Journal of medical case reports2024name in title: talimogene laherparepvec
PMID 38870745Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115.European journal of cancer (Oxford, England : 1990)2024name in title: talimogene laherparepvec
PMID 39159678A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2024name in title: talimogene laherparepvec
PMID 39429342Intralesional Talimogene Laherparepvec Immunotherapy for Melanoma: A Case Study.Cureus2024name in title: talimogene laherparepvec
PMID 39562006Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy.Journal for immunotherapy of cancer2024name in title: T-VEC
PMID 35797609Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice.Annals of surgery2023name in abstract: talimogene laherparepvec
PMID 35998300Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023name in title: talimogene laherparepvec
PMID 36564918Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma.CPT: pharmacometrics & systems pharmacology2023name in title: talimogene laherparepvec
PMID 36620496Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec.JAAD case reports2023name in title: talimogene laherparepvec
PMID 36648215Neoadjuvant treatment for stage III and IV cutaneous melanoma.The Cochrane database of systematic reviews2023cited by trial NCT02211131
PMID 36759673Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.Nature medicine2023cited by trial NCT02779855
PMID 36863095Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases.ESMO open2023name in title: talimogene laherparepvec
PMID 36959781Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation.Frontiers in oncology2023name in title: T-VEC
PMID 37142291Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.Journal for immunotherapy of cancer2023name in title: talimogene laherparepvec
PMID 37383323Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient.Case reports in dermatology2023name in title: talimogene laherparepvec
PMID 37561473Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial.JAMA oncology2023name in title: talimogene laherparepvec
PMID 37621406A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer.Cancer research communications2023cited by trial NCT04185311
PMID 37711513Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec.JAAD case reports2023name in title: talimogene laherparepvec
PMID 34519839The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides.Cancer immunology, immunotherapy : CII2022cited by trial NCT02890368
PMID 35115306Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells.Clinical cancer research : an official journal of the American Association for Cancer Research2022cited by trial NCT02923778
PMID 35499413Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy.Dermatology online journal2022name in title: talimogene laherparepvec
PMID 35656636A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma.Cancer science2022name in title: talimogene laherparepvec
PMID 35666757Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma.The Australasian journal of dermatology2022name in title: talimogene laherparepvec
PMID 35927710Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.BMC cancer2022cited by trial NCT04330430
PMID 36113895Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial.Journal for immunotherapy of cancer2022cited by trial NCT03747744
PMID 36262357Durable melanoma control following disseminated talimogene laherparepvec herpetic infection.JAAD case reports2022name in title: talimogene laherparepvec
PMID 36312666Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma.Cureus2022name in title: talimogene laherparepvec
PMID 36387105Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma.Frontiers in oncology2022name in abstract: talimogene laherparepvec
PMID 32897942Complete and Sustained Remission of Metastatic Cutaneous Squamous Cell Carcinoma in a Liver Transplant Patient Treated With Talimogene Laherparepvec.Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]2021name in title: talimogene laherparepvec
PMID 33219014A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2021name in title: talimogene laherparepvec
PMID 33608376Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.Journal for immunotherapy of cancer2021name in title: talimogene laherparepvec
PMID 33785610Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.Journal for immunotherapy of cancer2021name in title: talimogene laherparepvec
PMID 34132224Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018.Melanoma research2021cited by trial NCT03555032
PMID 34189749Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma.Journal of cutaneous pathology2021name in title: talimogene laherparepvec
PMID 34195326Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient.JAAD case reports2021name in title: talimogene laherparepvec
PMID 34235758False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC).Journal of surgical oncology2021name in title: talimogene laherparepvec
PMID 34330766Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial.Journal for immunotherapy of cancer2021cited by trial NCT02453191
PMID 34437665A Case of Recurrent Malignant Melanoma of the Left Foot with In-Transit Metastases.Rhode Island medical journal (2013)2021name in abstract: talimogene laherparepvec
PMID 34608333Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.Nature medicine2021name in title: talimogene laherparepvec
PMID 34627593Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.The Lancet. Haematology2021cited by trial NCT02890368
PMID 34782633A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer.Scientific reports2021name in title: talimogene laherparepvec
PMID 31815902Talimogene Laherparepvec Use in Kidney Transplant Recipient.Transplantation2020name in title: talimogene laherparepvec
PMID 31971541Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.JAMA oncology2020cited by trial NCT03069378
PMID 32050787Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database.Future oncology (London, England)2020name in title: talimogene laherparepvec
PMID 32235165Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy.Journal of immunotherapy (Hagerstown, Md. : 1997)2020name in title: T-VEC
PMID 32457834Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.Frontiers in oncology2020name in title: talimogene laherparepvec
PMID 32633563SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.Future oncology (London, England)2020cited by trial NCT03802604
PMID 32665184Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.Oral oncology2020name in title: talimogene laherparepvec
PMID 32669371Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.Clinical cancer research : an official journal of the American Association for Cancer Research2020cited by trial NCT02626000
PMID 32840157Retreatment with talimogene laherparepvec for advanced melanoma.Immunotherapy2020name in title: talimogene laherparepvec
PMID 33395852Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma.International journal of surgery case reports2020name in abstract: talimogene laherparepvec
PMID 33447351Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation.Oncotarget2020name in title: T-VEC
PMID 30211812Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.Melanoma research2019name in title: talimogene laherparepvec
PMID 30281140Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response.Acta dermato-venereologica2019name in title: talimogene laherparepvec
PMID 30414194The histological spectrum of talimogene laherparepvec (TVEC) injections-Neutrophilic and chronic granulomatous dermatitis.Journal of cutaneous pathology2019name in title: talimogene laherparepvec
PMID 30477000Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.JAMA dermatology2019name in title: talimogene laherparepvec
PMID 30690076Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.Journal of the American College of Surgeons2019name in title: talimogene laherparepvec
PMID 30698924Regression of mucosal melanoma following intralesional talimogene laherparepvec (T-VEC) injection in combination with immunotherapy.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2019name in title: talimogene laherparepvec
PMID 30758504Extensive Pigment Incontinence Mimicking Persistent Melanoma After Talimogene Laherparepvec Therapy.JAMA dermatology2019name in title: talimogene laherparepvec
PMID 30776080Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.The British journal of dermatology2019name in title: talimogene laherparepvec
PMID 30920764Rash after a single injection of T-VEC.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2019name in title: T-VEC
PMID 30933044Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.Journal of immunotherapy (Hagerstown, Md. : 1997)2019name in title: talimogene laherparepvec
PMID 30963012Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma.Case reports in oncological medicine2019name in title: talimogene laherparepvec
PMID 31171039Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.Journal for immunotherapy of cancer2019cited by trial NCT00769704
PMID 31264725Correlates of response and outcomes with talimogene laherperpvec.Journal of surgical oncology2019name in abstract: talimogene laherparepvec
PMID 31353364Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.British journal of cancer2019name in title: talimogene laherparepvec
PMID 31409575Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.EBioMedicine2019name in title: talimogene laherparepvec
PMID 31414290Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size.Annals of surgical oncology2019name in title: talimogene laherparepvec
PMID 31516997Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients.JAAD case reports2019name in title: talimogene laherparepvec
PMID 31649970Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma.JAAD case reports2019name in title: talimogene laherparepvec
PMID 28940544Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.Journal of cutaneous pathology2018name in title: talimogene laherparepvec
PMID 28981385Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2018name in title: talimogene laherparepvec
PMID 29112524Dermoscopic Guidance of Talimogene Laherparepvec Injection for Metastatic Melanoma.Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]2018name in title: talimogene laherparepvec
PMID 29176501Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.Melanoma research2018name in title: talimogene laherparepvec
PMID 29561296Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.Melanoma research2018cited by trial NCT02147951
PMID 29622046Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.Journal for immunotherapy of cancer2018name in title: talimogene laherparepvec
PMID 29693076Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy.JAAD case reports2018name in title: talimogene laherparepvec
PMID 29764498Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series.Journal for immunotherapy of cancer2018name in title: talimogene laherparepvec
PMID 29896663Oncolytic Virotherapy by HSV.Advances in experimental medicine and biology2018cited by trial NCT02263508
PMID 30054925Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in-transit melanoma.Journal of cutaneous pathology2018name in title: talimogene laherparepvec
PMID 30450405Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma.JAAD case reports2018name in title: talimogene laherparepvec
PMID 30454071Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.Journal for immunotherapy of cancer2018name in title: talimogene laherparepvec
PMID 27922859FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec.Clinical nuclear medicine2017name in title: talimogene laherparepvec
PMID 28443305Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases.JAAD case reports2017name in title: talimogene laherparepvec
PMID 28445579Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate.JAMA dermatology2017name in title: talimogene laherparepvec
PMID 28481677Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab.Acta oncologica (Stockholm, Sweden)2017name in title: talimogene laherparepvec
PMID 28642816Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma.Journal for immunotherapy of cancer2017name in title: T-VEC
PMID 28653030Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec.JAAD case reports2017name in title: talimogene laherparepvec
PMID 28738934Neoadjuvant Talimogene Laherparepvec for the Treatment of Metastatic Melanoma.The American surgeon2017name in title: talimogene laherparepvec
PMID 28886381Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.Cell2017name in abstract: talimogene laherparepvec
PMID 28923101Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials.Journal for immunotherapy of cancer2017cited by trial NCT00769704
PMID 27298410Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2016name in title: talimogene laherparepvec
PMID 27342831Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.Annals of surgical oncology2016name in title: talimogene laherparepvec
PMID 27407058Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.Head & neck2016name in title: talimogene laherparepvec
PMID 26014293Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2015cited by trial NCT00769704
PMID 19915919Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.Annals of surgical oncology2010name in abstract: OncoVEX GM-CSF
PMID 20528232OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.Future oncology (London, England)2010name in abstract: OncoVEX GM-CSF
Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 32964173Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus.Journal of the Endocrine Society2020name in abstract: T-VEC

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 40329730Talimogene Laherparepvec (T-VEC): Expanding Horizons in Oncolytic Viral Therapy Across Multiple Cancer Types.Anti-cancer agents in medicinal chemistry2026name in title: talimogene laherparepvec
PMID 40939516Engineered oncolytic herpes simplex virus expressing interleukin 12 suppresses tumorigenicity of hepatocellular carcinoma.Biochimica et biophysica acta. Molecular basis of disease2026name in abstract: talimogene laherparepvec
PMID 41175341Opportunities and challenges in the clinical application of anticancer virotherapy.Expert review of anticancer therapy2026name in abstract: talimogene laherparepvec
PMID 41542033Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial.Molecular therapy. Oncology2026name in title: talimogene laherparepvec
PMID 41724916Evaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers.Annals of surgical oncology2026name in title: talimogene laherparepvec
PMID 41754610Enhanced Antitumor Activity and Induction of Immunogenic Cell Death in NUT Carcinoma Cells by Combining Oncolytic Viruses with the Dual Inhibitor NEO2734.Viruses2026name in abstract: talimogene laherparepvec
PMID 41772244ASO Visual Abstract: Evaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers.Annals of surgical oncology2026name in title: talimogene laherparepvec
PMID 41827827Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation.Cells2026name in abstract: talimogene laherparepvec
PMID 41901211Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines.Pharmaceuticals (Basel, Switzerland)2026name in abstract: talimogene laherparepvec
PMID 41990252Systemic Therapies for the Treatment of Cutaneous Malignancies in Solid Organ Transplant Recipients.Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]2026name in abstract: talimogene laherparepvec
PMID 42025901Efficacy of oncolytic viruses (OVs) in malignant tumor therapy: a review on its therapeutic aspects.Clinica chimica acta; international journal of clinical chemistry2026name in abstract: Imlygic
PMID 42130334Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials.Melanoma research2026name in abstract: talimogene laherparepvec
PMID 42204570Antitumor activity of Oncolytic Herpes Symplex Virus Type 1 and photodynamic therapy in in vitro preclinical models of glioblastoma.Journal of translational medicine2026name in abstract: talimogene laherparepvec
PMID 42216079Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies.Virology journal2026name in abstract: Imlygic
PMID 42327580Emerging Oncolytic Viruses: Beyond Adenoviruses and Herpes Simplex Virus.Journal of Cancer2026name in abstract: talimogene laherparepvec
PMID 42335571Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy.European journal of cancer (Oxford, England : 1990)2026name in abstract: talimogene laherparepvec
PMID 42346244The Evolving Role of Intralesional Therapy in In-Transit Melanoma.Current oncology (Toronto, Ont.)2026name in abstract: talimogene laherparepvec
PMID 42349466Updates on intratumoral therapies in melanoma.Cancer2026name in abstract: talimogene laherparepvec
PMID 42456895Oncolytic viruses in cancer therapy: Mechanisms, challenges, and emerging clinical applications.Annales pharmaceutiques francaises2026name in abstract: talimogene laherparepvec
PMID 42531348In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol.PLoS computational biology2026name in abstract: talimogene laherparepvec
PMID 42766303Vaccines for Cancer: A Translational Science Review.JAMA2026name in abstract: talimogene laherparepvec
PMID 42809340Combined talimogene laherparepvec and binimetinib in NRAS-mutated melanoma induces anti-tumor immunity.The Journal of clinical investigation2026name in title: talimogene laherparepvec
PMID 42886257Oncolytic virotherapy for cancer: biological mechanisms, clinical advances, and future perspectives.Clinical and experimental medicine2026name in abstract: talimogene laherparepvec
PMID 42910817Neoadjuvant Intralesional T-VEC Enabling Digit Preservation in Subungual Acral Melanoma.Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]2026name in title: T-VEC
PMID 42961021Neoadjuvant Therapy in Mohs Surgery: A Scoping Review of the Literature.Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]2026name in abstract: talimogene laherparepvec
PMID 42991423Intralesional and intratumoral therapies in melanoma: current evidence and future perspectives-a narrative review.Annals of translational medicine2026name in abstract: talimogene laherparepvec
PMID 39787519Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage colony-stimulating factor for metastatic melanoma: a systematic review and network meta-analysis of randomized controlled trials.Melanoma research2025name in title: talimogene laherparepvec
PMID 39819188Talimogene laherparepvec (T-VEC) as a treatment for melanoma: A systematic review.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2025name in title: talimogene laherparepvec
PMID 40004731Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy.Journal of clinical medicine2025name in title: T-VEC
PMID 40028913Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec.Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]2025name in title: talimogene laherparepvec
PMID 40171522Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2.Therapeutic advances in medical oncology2025name in title: talimogene laherparepvec
PMID 40213531Oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma - A systematic review.JAAD international2025name in abstract: talimogene laherparepvec
PMID 40365251Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here?Skin health and disease2025name in abstract: talimogene laherparepvec
PMID 40561062Neutralizing monoclonal antibodies improve biodistribution of intravenously administered oncolytic adenovirus in human CD46-transgenic mice.PloS one2025name in abstract: talimogene laherparepvec
PMID 40596452Real world pharmacovigilance study of antineoplastic drug related vitiligo risks.Scientific reports2025name in abstract: talimogene laherparepvec
PMID 40702727Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.Molecular therapy : the journal of the American Society of Gene Therapy2025name in abstract: Imlygic
PMID 40733704Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review.Vaccines2025name in abstract: talimogene laherparepvec
PMID 40784659Analysis of talimogene laherparepvec (T-VEC) safety signals from food and drug administration adverse event reporting system (FAERS).European journal of pharmacology2025name in title: talimogene laherparepvec
PMID 40827547In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation.Advanced science (Weinheim, Baden-Wurttemberg, Germany)2025name in abstract: talimogene laherparepvec
PMID 40872965Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook.Vaccines2025name in abstract: talimogene laherparepvec
PMID 40881284Oncolytic viruses in head and neck cancers: clinical applications and therapeutic potential.Frontiers in microbiology2025name in abstract: talimogene laherparepvec
PMID 40928075Anatomic Location Predicts Response Rates: Real World Outcomes With Over 1100 Cycles of Talimogene Laherparepvec Description: A Retrospective Review of a Prospectively Maintained Database.Annals of surgery2025name in title: talimogene laherparepvec
PMID 41148835The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond.Cells2025name in title: talimogene laherparepvec
PMID 41448830Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma.Journal for immunotherapy of cancer2025name in title: talimogene laherparepvec
PMID 41451911Melanosis Secondary to Drugs: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)2025name in abstract: talimogene laherparepvec
PMID 41835051Hydrogel Micro/Nanostructures for the Delivery of Oncolytic Viruses: Overcoming Limitations and Improving Efficacy.Advanced pharmaceutical bulletin2025name in abstract: talimogene laherparepvec
PMID 37578289Clinical updates in neoadjuvant immunotherapy for melanoma before surgery.Expert review of clinical immunology2024name in abstract: talimogene laherparepvec
PMID 37877961Oncolytic viral therapy: a review and promising future directions.Journal of neurosurgery2024name in abstract: talimogene laherparepvec
PMID 38224076Clinical and Histological Response to Talimogene Laherparepvec Therapy in Advanced Melanoma: Impact on Overall Survival.Journal of the American College of Surgeons2024name in title: talimogene laherparepvec
PMID 38444199Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1.Immunology2024name in abstract: talimogene laherparepvec
PMID 38527264Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma.Cancer journal (Sudbury, Mass.)2024name in abstract: talimogene laherparepvec
PMID 38562109Rescue Rates for Talimogene laherparepvec Use in Loco-Regionally Progressing Cutaneous Melanoma Refractory to PD1 Inhibition.The American surgeon2024name in title: talimogene laherparepvec
PMID 38576614New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.Frontiers in immunology2024name in abstract: talimogene laherparepvec
PMID 38599661Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.Journal for immunotherapy of cancer2024name in abstract: talimogene laherparepvec
PMID 38793657Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors.Viruses2024name in title: talimogene laherparepvec
PMID 38821716Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?Journal for immunotherapy of cancer2024name in abstract: talimogene laherparepvec
PMID 38893072Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma.Cancers2024name in title: talimogene laherparepvec
PMID 38893078Intralesional and Infusional Updates for Metastatic Melanoma.Cancers2024name in abstract: talimogene laherparepvec
PMID 38921005Targeting Cancers with oHSV-Based Oncolytic Viral Immunotherapy.Current issues in molecular biology2024name in abstract: Imlygic
PMID 39040851Translation of oncolytic viruses in sarcoma.Molecular therapy. Oncology2024name in abstract: talimogene laherparepvec
PMID 39065766Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies?Pharmaceuticals (Basel, Switzerland)2024name in abstract: talimogene laherparepvec
PMID 39229331Beyond the Scalpel: Advancing Strategic Approaches and Targeted Therapies in Nonexcisable Melanomas.Journal of skin cancer2024name in abstract: talimogene laherparepvec
PMID 39326128Advances in the management of regionally metastatic melanoma.Surgical oncology2024name in abstract: talimogene laherparepvec
PMID 39456110Ultrasound-guided intra-tumoral administration of directly-injected therapies: a review of the technical and logistical considerations.Cancer imaging : the official publication of the International Cancer Imaging Society2024name in abstract: talimogene laherparepvec
PMID 39602056Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review.Current oncology reports2024name in title: talimogene laherparepvec
PMID 39682138Adjuvant Radiation Therapy in Macroscopic Regional Nodal Melanoma.Cancers2024name in abstract: talimogene laherparepvec
PMID 39687659A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma.Clinical case reports2024name in title: talimogene laherparepvec
PMID 39696696Safety of talimogene laherparepvec: a real-world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS).Journal of pharmaceutical health care and sciences2024name in title: talimogene laherparepvec
PMID 39796696Topical and Intralesional Treatments for Skin Metastases and Locoregionally Advanced Melanoma.Cancers2024name in abstract: talimogene laherparepvec
PMID 36299168Oncolytic virus preclinical toxicology studies.Journal of applied toxicology : JAT2023name in abstract: talimogene laherparepvec
Unconfirmed matches (30)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 40920359A new frontier in oncology: Understanding the landscape of cancer vaccines.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2026name in abstract: T-VEC
PMID 41403403Engineering HSV-1 for oncolytic therapy: From molecular entry mechanisms to retargeting strategies.Genes & diseases2026name in abstract: T-VEC
PMID 41485410Overcoming resistance in oncolytic virotherapy: Nano-engineered solutions for systemic delivery and efficacy boost.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy2026name in abstract: T-VEC
PMID 41675687Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery.Molecular therapy. Oncology2026name in abstract: T-VEC
PMID 41705010A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy.Cureus2026name in abstract: T-VEC
PMID 42313150[Therapy of melanoma : Current standards and future perspectives].Pathologie (Heidelberg, Germany)2026name in abstract: T-VEC
PMID 42344931Vaccines as treatment for melanoma: an update review.Frontiers in immunology2026name in abstract: T-VEC
PMID 42504409Oncolytic Virotherapy, Long Stalled, Nears Second Approval.Cancer discovery2026name in abstract: T-VEC
PMID 42648642Engineering HSV-1 for gene therapy, oncolytic immunotherapy, and neuroscience.Virologica Sinica2026name in abstract: T-VEC
PMID 43005928The synthetic biology frontier: engineered oncolytic viruses and viral vectors for next-generation cancer therapy and gene delivery.RSC advances2026name in abstract: T-VEC
PMID 39422848Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis.Annals of surgical oncology2025name in abstract: T-VEC
PMID 40069043HSV-1 as a gene delivery platform for cancer gene therapy.Trends in pharmacological sciences2025name in abstract: T-VEC
PMID 40123637Cancer Vaccines: A Novel Revolutionized Approach to Cancer Therapy.Indian journal of clinical biochemistry : IJCB2025name in abstract: T-VEC
PMID 40223683In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment.ACS biomaterials science & engineering2025name in abstract: T-VEC
PMID 40285023Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus.Viruses2025name in abstract: T-VEC
PMID 40305928Advances and challenges in cancer immunotherapy: Strategies for personalized treatment.Seminars in oncology2025name in abstract: T-VEC
PMID 40685482Oncolytic virotherapy and tumor microenvironment modulation.Clinical and experimental medicine2025name in abstract: T-VEC
PMID 40977706Opportunities, challenges, and future perspectives of oncolytic virus therapy for malignant melanoma.Frontiers in immunology2025name in abstract: T-VEC
PMID 40991899A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses.Cancer control : journal of the Moffitt Cancer Center2025name in abstract: T-VEC
PMID 41296382Recombinant Oncolytic Viruses: Hexagonal Warriors in the Field of Solid Tumor Immunotherapy.Current issues in molecular biology2025name in abstract: T-VEC
PMID 41463198Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions.Cancers2025name in abstract: T-VEC
PMID 41662640Review Article: Intratumoral Immunotherapy: Old Discoveries and Recent Developments in Sarcomas.Critical reviews in oncogenesis2025name in abstract: T-VEC
PMID 38171406Advances and prospects of mRNA vaccines in cancer immunotherapy.Biochimica et biophysica acta. Reviews on cancer2024name in abstract: T-VEC
PMID 38435173HIV-Encoded Gene Therapy as Anti-cancer Therapeutics: A Narrative Review.Cureus2024name in abstract: T-VEC
PMID 38750345Access to melanoma drugs in Spain: a cross-sectional survey.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2024name in abstract: T-VEC
PMID 38941955Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures.EBioMedicine2024name in abstract: T-VEC
PMID 39044819Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.Frontiers in immunology2024name in abstract: T-VEC
PMID 39239066Synergistic effects of herpes oncolytic virus and cyclophosphamide for recurrent malignant glioma: a narrative review.Annals of medicine and surgery (2012)2024name in abstract: T-VEC
PMID 39293238Breaking Barriers: Animal viruses as oncolytic and immunotherapeutic agents for human cancers.Virology2024name in abstract: T-VEC
PMID 36044068Local anesthetics and immunotherapy: a novel combination to fight cancer.Seminars in immunopathology2023name in abstract: T-VEC

NIH grants

ProjectTitleOrganisationPIYearsLinked by
P01CA163205Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapyBRIGHAM AND WOMEN'S HOSPITALKAUR, BALVEEN2023–2026name in abstract: Imlygic
R01CA269002Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunityUNIVERSITY OF HOUSTONZHANG, SHAUN XIAOLIU2022–2026name in abstract: talimogene laherparepvec
R21CA303392Boosting Oncolytic HSV Immunotherapy by Enabling NecroptosisLOUISIANA STATE UNIV HSC SHREVEPORTGUO, HONGYAN2025–2025name in abstract: talimogene laherparepvec
R43CA298595Preclinical development of VAX024 - a novel targeted combination STING agonist/oncolytic agentVAXIION THERAPEUTICS, INC.GIACALONE, MATTHEW2025–2025name in abstract: Imlygic
R21NS123685IGF1R-targeted oncolytic herpes simplex viral therapy for GlioblastomaUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTONYOO, JI YOUNG2022–2023name in abstract: talimogene laherparepvec
R43HG012745Development of GenomeBuild as a Universal Method to Synthesize GenomesPROTEOVISTA, LLCWARREN, CHRISTOPHER L2023–2023name in abstract: talimogene laherparepvec
R33NS112410Optimizing oncolytic virus therapy for glioblastomaAUGUSTA UNIVERSITYKAUR, BALVEEN2022–2022name in abstract: Imlygic
F31CA235898Developing polycistronic replication-defective herpes simplex virus vectors as immunotherapeutic tools for treating melanomaHARVARD MEDICAL SCHOOLWALSH, MICHAEL2020–2020name in abstract: talimogene laherparepvec
R01FD006108Ph1 Study of T-Vec given endoscopically for advanced pancreatic cancer IN 17248 (11/21/2016)COLUMBIA UNIVERSITY HEALTH SCIENCESSAENGER, YVONNE MARGARET2018–2020name in title: T-VEC
R61NS112410Optimizing oncolytic virus therapy for glioblastomaUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTONKAUR, BALVEEN2019–2020name in abstract: Imlygic
75N91019D00Biopsy Support with Patients with Advanced MelanomaLEIDOS BIOMEDICAL RESEARCH, INC.FREEDMAND, LEONARD2019–2019name in abstract: talimogene laherparepvec
F32NS108528Oncolytic virotherapy targeting RAGE signaling in glioblastomaUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTONSWANNER, JESSICA2018–2018name in abstract: talimogene laherparepvec
Unconfirmed matches (4)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

ProjectTitleOrganisationPIYearsLinked by
R01CA224605Dual-pronged nano-drug delivery using plant virus-like particles.UNIVERSITY OF CALIFORNIA, SAN DIEGOSTEINMETZ, NICOLE FRANZISKA2017–2021name in abstract: T-VEC
U01CA218292Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.UNIVERSITY OF CALIFORNIA, SAN DIEGOSTEINMETZ, NICOLE FRANZISKA2017–2021name in abstract: T-VEC
R44CA233024Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumorsVYRIAD, INC.RUSSELL, LUKE O.2018–2020name in abstract: T-VEC
R01CA187923Novel Strategies to Potentiate a Ras-targeted Oncolytic Herpes Simplex VirusUNIVERSITY OF HOUSTONZHANG, SHAUN XIAOLIU2015–2019name in abstract: T-VEC

Notes

FDA approved 2015 as Imlygic; BioVex acquired by Amgen 2011. OncoVEX GM-CSF was the BioVex-era development name. Transgenes moved from targets to virus.tsv (spec 0.2).

How to cite

talimogene laherparepvec (AXP000001.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000001.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.